Fig. 6From: Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapySchematic of the hypothesized interaction between upstream α-synuclein and downstream tau toxicity. Oligomeric α-synuclein cross-seeds tau, inducing its oligomerization, leading to downstream toxicity that is inhibited by immunotherapy against tau oligomersBack to article page